AI could reduce pharma R&D costs by 30% to 40% and shorten timelines by one to four years. The partnership expands Lilly’s existing AI supercomputer project with Nvidia’s DGX technology. Are you ahead ...
It was just three months ago that Nvidia turned heads in the tech world with the DGX Spark, a $4,000 desktop supercomputer that was meant to help democratize AI beyond corporate giants. Things move ...
Eli Lilly and Nvidia are putting up to $1 billion on the table to see whether generative AI can compress the decade-long slog of drug development into something closer to a software cycle. The two ...
Eli Lilly (LLY) and Nvidia (NVDA) will invest up to $1B over five years in an AI drug discovery lab. AI could reduce pharma R&D costs by 30% to 40% and shorten timelines by one to four years. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results